| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 84511 |
Fmoc-PEG3-Val-Cit，N-Fluorenylmethoxycarbonyl-triethylene glycol-Val-Cit |
154 |
WYQ |
2024-12-19 |
| 84512 |
CAS: 2226472-28-0，DBCO-PEG4-Val-Cit-PAB-PNP |
121 |
WYQ |
2024-12-19 |
| 84513 |
CAS: 2055024-64-9，Azido-PEG4-Val-Cit-PAB-OH |
149 |
WYQ |
2024-12-19 |
| 84514 |
CAS: 870487-09-5，Boc-Val-Cit-PAB |
145 |
WYQ |
2024-12-19 |
| 84515 |
CAS:784105-33-5 Amino-PEG3-C2-acid的介绍 |
130 |
zyl |
2024-12-19 |
| 84516 |
CAS 863971-53-3：Fmoc-Val-Cit-PAB-PNP |
132 |
WYQ |
2024-12-19 |
| 84517 |
Ald-Ph-amido-PEG11-C2-NH2 CAS:1337889-01-6 |
129 |
zyl |
2024-12-19 |
| 84518 |
cas:2003260-13-5 ， MA-PEG4-Ala-Ala-PAB-PNP，ADC定制 |
146 |
wyh |
2024-12-19 |
| 84519 |
DOTA-NCS-6-Ahx-Phe 19-ST[1-19] DOTA偶联ST肽类似物 |
165 |
h |
2024-12-19 |
| 84520 |
1,4,7,10-四氮杂-n-(1-羧基-3-(4-硝基苯基)丙基)-n,N , N ‴-tris(acetic酸)环十二烷(PA-DOTA) |
121 |
h |
2024-12-19 |
| 84521 |
CAS 159858-22-7：Fmoc-Val-Cit-PAB-OH |
133 |
WYQ |
2024-12-19 |
| 84522 |
cas:5117-19-1，Octanethyl glycol ，八乙二醇的主要特点 |
228 |
zyl |
2024-12-19 |
| 84523 |
CAS 159857-79-1：Val-Cit-PAB-OH，缬氨酸（Val）、琥珀酰亚胺（Cit）和对氨基苯甲酸（PAB）的衍生物 |
171 |
WYQ |
2024-12-19 |
| 84524 |
SPDP-Val-Cit-PAB-OH，ADC定制 |
129 |
wyh |
2024-12-19 |
| 84525 |
DOTA-LVT 螯合剂DOTA偶联Lys8-血管收缩素 |
213 |
h |
2024-12-19 |
| 84526 |
cas:2054345-67-2，azido-tris(ethylenoxy)-L-alanine TFA Salt化学性质 |
144 |
zyl |
2024-12-19 |
| 84527 |
cas:68617-64-1，SPDP acid，3-(2-吡啶二硫代)丙酸的合成方法 |
202 |
zyl |
2024-12-19 |
| 84528 |
1,4,7,10-四(羧甲基)-1,4,7,10-四氮杂环十二烷单酰胺偶联葡萄糖 |
165 |
h |
2024-12-19 |
| 84529 |
PEG-P(Asp-Gd-DOTA)Gd‐DOTA偶联聚乙二醇改性聚天冬氨酸 |
164 |
h |
2024-12-19 |
| 84530 |
cas:70539-42-3，EGS Crosslinker，乙二醇-双(琥珀酸N-羟基琥珀酰亚胺酯)的结构式 |
345 |
zyl |
2024-12-19 |
| 84531 |
CXCR4导向的五肽[(68)Ga]喷替沙福(环(-D-Tyr-N-Me-D-Orn(AMB-DOTA)-L-Arg-L-2-Nal-Gly-)) |
210 |
h |
2024-12-19 |
| 84532 |
α-hexadecyl-DOTA α-十六烷基-DOTA |
159 |
h |
2024-12-19 |
| 84533 |
Methyltetrazine-SS-NHS 甲基四唑-双硫键-活性酯的合成方法 |
153 |
zyl |
2024-12-19 |
| 84534 |
DOTA-AgRP-6E |
188 |
h |
2024-12-19 |
| 84535 |
DOTA-morab-003 DOTA偶联单克隆抗体MORAb-003 |
177 |
h |
2024-12-19 |
| 84536 |
DOTA-Bz-folate DOTA-Bz-叶酸 |
160 |
h |
2024-12-19 |
| 84537 |
cas:55750-53-3，6-Maleimidocaproic acid，6-马来酰亚氨基己酸 |
207 |
zyl |
2024-12-19 |
| 84538 |
cas: Fmoc-PEG3-Val-Cit，ADC定制 |
184 |
wyh |
2024-12-19 |
| 84539 |
钆(III)DOTA-DSPE脂质体 |
163 |
h |
2024-12-19 |
| 84540 |
CAS: 870487-08-4，Boc-Val-Cit，叔丁氧羰基-缬氨酰-L-瓜氨酸 |
130 |
WYQ |
2024-12-19 |
| 84541 |
DOTA-Phe-D-Trp-Lys-Thr-OMe DOTA偶联生长抑素四肽类似物 |
197 |
h |
2024-12-19 |
| 84542 |
CAS: 35665-38-4，Fmoc-Gly-Gly-OH，Fmoc-甘氨酰-甘氨酸 |
187 |
WYQ |
2024-12-19 |
| 84543 |
cas:117235-10-6，3-Mercaptopropanyl-N-hydroxysuccinimide ester的结构式 |
178 |
zyl |
2024-12-19 |
| 84544 |
DOTA-PEG(4)-BBN(7-14)-AuNP DOTA-神经介素n功能化NHS活化的PEG-金纳米颗粒 |
155 |
h |
2024-12-19 |
| 84545 |
cas:2226472-28-0，DBCO-PEG4-Val-Cit-PAB-PNP，ADC定制 |
123 |
wyh |
2024-12-19 |
| 84546 |
CAS: 863971-53-3，Fmoc-Val-Cit-PAB-PNP |
143 |
WYQ |
2024-12-19 |
| 84547 |
tris-苄基-DOTA tris-benzyl-DOTA |
175 |
h |
2024-12-19 |
| 84548 |
DOTA-DN(PTX)-BN DOTA-铃蟾肽功能化聚酰胺胺(PAMAM)树状大分子(DN)负载紫杉醇 |
162 |
h |
2024-12-19 |
| 84549 |
NH2-Sar10-COOH，ADC定制 |
165 |
wyh |
2024-12-19 |
| 84550 |
cas:1415328-95-8，NHPI-PEG4-C2-NHS ester |
183 |
zyl |
2024-12-19 |
| 84551 |
Gd-GlyMe-DOTA-全氟辛基甘露糖缀合物(Gadofluorine M) |
219 |
h |
2024-12-19 |
| 84552 |
MC-Val-Cit-PAB-PNP（CAS号：159857-81-5） |
174 |
WYQ |
2024-12-19 |
| 84553 |
Mal-Gly-Gly-L-Phe-N-[(carboxymethoxy)methyl]Glycinamide，ADC定制 |
145 |
wyh |
2024-12-19 |
| 84554 |
L-RNA寡核苷酸的功能化DOTA |
158 |
h |
2024-12-19 |
| 84555 |
MA-PEG4-Glu(t-Bu)-Val-Cit-PAB-PNP，在药物递送系统中具有广泛应用潜力 |
150 |
WYQ |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询